Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientcellsbirthchemotherapycell
  Phrases that lowered it: lymphomapatientspulmonary diseaseinvestigatorchronic obstructive
• Sponsor's past termination rate: 26.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 12.4% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 1.81709e+06 (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 23 (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 1031 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 77.9% (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 207273 (lowers risk) · Drug's FDA history
• Maximum age: 70 (lowers risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia NCT04342962 · started 2021 · scored riskier than 77% of active trials terminated
• Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia NCT02113982 · started 2014 · scored riskier than 92% of active trials completed
• AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia NCT01431664 · started 2011 · scored riskier than 77% of active trials completed
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia NCT02420717 · started 2015 · scored riskier than 86% of active trials terminated
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial NCT03735446 · started 2019 · scored riskier than 97% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.